FiercePharma5d
Novo Nordisk wins hard-fought FDA approval for once-daily hemophilia med Alhemo
Late last week, Novo revealed that the FDA approved its tissue factor pathway inhibitor (TFPI) antagonist concizumab as a once-a-day treatment to prevent or curb the frequency of bleeding episodes ...
pharmaphorum7d
ASH: Pfizer builds case for long-acting haemophilia drug
The anti-tissue factor pathway inhibitor (TFPI) drug was effective at reducing annualised bleeding rates (ABR) in patients with haemophilia A and B in the BASIS trial, improving on standard ...
The American Journal of Managed Care5d
First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA
Concizumab is a tissue factor pathway inhibitor (TFPI) antagonist designed to enhance thrombin production by blocking TFPI—a protein that disrupts blood clotting. Doing so helps patients with ...
pharmaphorum1y
Novo Nordisk's concizumab hits mark in haemophilia, but dosing questioned
The results of the Explorer7 trial showed that concizumab – an anti-tissue factor pathway inhibitor (TFPI) antibody – reduced the number of treated bleeds in patients by 86% when given as a ...